ESTRO 2024 - Abstract Book

S2143

Clinical - Upper GI

ESTRO 2024

6. Song Y, Wang W, Tao G, Zhu W, Zhou X, Pan P. Survival benefit of radiotherapy to patients with small cell esophagus carcinoma: an analysis of Surveillance Epidemiology and End Results (SEER) data. Oncotarget . 2016;7(13):15474-15480.

7. Xu L, Li Y, Liu X, et al. Treatment strategies and prognostic factors of limited-stage primary small cell carcinoma of the esophagus. J Thorac Oncol . 2017;12(12):1834-1844.

8. Patel S, TenNapel M, Clamon G, Bhatia S. Small cell carcinoma of the esophagus: the SEER experience from 2000-2009. Int J Radiat Oncol Biol Phys . 2013;87(2):S292.

9. Verma V, Sleightholm RL, Fang P, Ryckman JM, Lin C. National Cancer Database report of nonmetastatic esophageal small cell carcinoma. Cancer Med . 2018;7(12):6365-6373.

10. Wong AT, Shao M, Rineer J, Osborn V, Schwartz D, Schreiber D. Treatment and survival outcomes of small cell carcinoma of the esophagus: an analysis of the National Cancer Data Base. Dis Esophagus . 2017;30(2):1-5.

11. Li T, Chen S, Zhang Z, et al. Chemotherapy plus radiotherapy versus radiotherapy in patients with small cell carcinoma of the esophagus: a SEER database analysis. Cancer Control . 2021;28:1073274821989321.

434

Digital Poster

Optimal Time-to-Surgery for Patients with Esophageal Cancer after Neoadjuvant Chemoradiotherapy

QIFENG WANG 1,2 , Jingqiu Li 1,2 , xiaoding zhou 1,2 , Ying Liu 1,2 , Jie Zhu 1,2 , Xuefeng Leng 3 , Lin Peng 3 , Yongtao Han 3

1 Sichuan Cancer Center, Radiation Oncology, Chengdu, China. 2 Sichuan province, Radiation Oncology Key Lab, Chengdu, China. 3 Sichuan Cancer Center, Thoracic surgery, Chengdu, China

Purpose/Objective:

Neoadjuvant chemoradiotherapy (NCRT) has shown promise in improving the prognosis of individuals with locally advanced esophageal squamous cell carcinoma (LA-ESCC). However, the factors influencing tumor response and long-term survival in these patients remain unknown. The optimal timing for surgery after the completion of radiotherapy in LA-ESCC remains controversial. Therefore, this study aimed to identify biomarkers and determine the optimal post-NCRT time-to-surgery (TTS) for patients with LA-ESCC.

Material/Methods:

This retrospective study included patients with resectable LA-ESCC who underwent NCRT between May 2017 and June 2021. The tumor shrinkage rate was calculated as the difference between the pre- and post-primary gross tumor volume (GTVp) divided by the pre-GTVp. Univariate and multivariate Cox regression analyses and Kaplan – Meier curves were used to calculate overall survival (OS) and progression-free survival (PFS).This study received